Gleevec, Sprycel and Tasigna are all prescription medicines used to treat chronic myelogenous leukemia (blood cancer). Gleevec and Sprycel are also approved for other types of cancers and tumors. These drugs are all classified as BCR-ABL kinase inhibitors and block the enzyme BCR-ABL tyrosine kinase, which is an important pathway in the development of leukemia.